Additionally, although our preliminary in vivo experiments demonstrate protective effects of anti-uPAR therapy against AKI, further elucidation of its underlying pathophysiological mechanisms and optimization of monoclonal antibody administration parameters (dose, timing, delivery method) are required. Here, PLAUR is linked to acute kidney injury.